arih1l Antibody

What is ASH1L and why is it important in research?

ASH1L is a histone lysine methyltransferase that catalyzes the mono- and dimethylation of histone H3 at lysine 36 (H3K36), representing an activating mark on chromatin . It is a large protein (~3000 amino acids) containing a catalytic SET domain responsible for transferring methyl groups from S-adenosyl methionine (SAM) to lysine substrates . ASH1L is important because it regulates gene expression and has been implicated in various diseases, particularly cancers such as acute leukemia and anaplastic thyroid cancer . ASH1L associates with the transcribed region of active genes and is not detected at inactive genes, suggesting its role in active transcription .

What epitopes do ASH1L antibodies typically recognize?

ASH1L antibodies have been designed to recognize various epitopes within the protein. Commercial antibodies such as ASH5H03 detect human ASH1L protein . Research-based antibodies have been developed against distinct epitopes in the N-terminus (amino acids 8-146, antibody 337ap) and middle portion (amino acids 1612-1767, antibody 296) of ASH1L . The commercial antibody ab4477 targets amino acids 1650-1750 . These antibodies recognize both human and mouse orthologs due to sequence homology .

What are the primary applications for ASH1L antibodies in research?

ASH1L antibodies are primarily used for:

• Western blotting (WB) to detect ASH1L protein expression levels

• Immunoprecipitation (IP) to isolate ASH1L protein complexes

• Chromatin immunoprecipitation (ChIP) assays to study ASH1L occupancy on specific genomic regions

• ChIP-sequencing to profile genome-wide binding patterns of ASH1L

• Validating ASH1L knockdown or knockout in functional studies

How should I design a ChIP experiment to study ASH1L binding patterns?

For optimal ChIP experiments with ASH1L antibodies:

• Cross-linking protocol: Perform dual cross-linking with both ethylene glycol bis(succinimidyl succinate) (34.5 mg in 5 ml DMSO for 30 min) and 1% formaldehyde for optimal results, as ASH1L may require enhanced cross-linking .

• Antibody selection: Use validated ChIP-grade antibodies. Multiple independently derived antibodies (such as 296, 337ap, and ab4477) should be tested to confirm results .

• Controls: Include inactive genes (e.g., CD4 and MYT1) as negative controls and known ASH1L-bound active genes (e.g., RPLP0, PPIA, RPS2) as positive controls .

• Quantification: Perform real-time PCR using SYBR green dye with appropriate standards made via serial dilution of unprecipitated input samples .

• Validation: Confirm antibody specificity using shRNA or CRISPR-mediated knockdown/knockout of ASH1L .

How can I profile ASH1L occupancy across a gene of interest?

To profile ASH1L occupancy across a gene:

• Design primer pairs covering multiple regions: upstream of the transcription start site (TSS), near the promoter, throughout the transcribed portion, and downstream of the poly(A) signal .

• Focus particularly on the region +0.5 to 1.0 kb downstream of the TSS, where ASH1L occupancy is typically highest .

• Compare ASH1L occupancy with histone modifications: H3K4 trimethylation (typically restricted to the 5'-transcribed region), H3K9 trimethylation (limited to the 3' portion), and H4K20 monomethylation (throughout the transcribed region) .

• For genome-wide profiling, perform ChIP-seq analysis, dividing the genome into enhancers and other genic regions, and calculate the average immunoprecipitation-over-input signal per base pair .

What controls should be included when validating ASH1L antibody specificity?

To validate ASH1L antibody specificity:

• Genetic knockdown/knockout controls: Include ASH1L shRNA knockdown or CRISPR-Cas9 knockout samples to confirm antibody specificity. The signal should significantly decrease in these samples .

• Multiple antibodies: Use at least two independent antibodies targeting different epitopes of ASH1L to ensure consistent results .

• Positive and negative controls: Include cell types known to express high (e.g., ATC cell lines like BHT-101, SW1736, JEM493) and low (e.g., certain PTC cell lines) levels of ASH1L .

• Cross-reactivity testing: Test antibody reactivity against closely related proteins to ensure specificity .

• Isotype controls: Include appropriate isotype controls (e.g., mouse IgG1 κ for ASH5H03) to account for non-specific binding .

How can I investigate ASH1L's role in cancer using antibody-based approaches?

To investigate ASH1L's role in cancer:

• Expression analysis: Perform Western blotting of nuclear extracts from cancer tissues and matched normal tissues to quantify ASH1L protein expression, normalizing to nuclear markers like lamin B1 .

• ChIP-seq analysis: Map genome-wide binding patterns of ASH1L in cancer cells to identify target genes and regulatory elements .

• Functional validation: After ASH1L knockdown or knockout, use antibodies to monitor changes in histone modifications (e.g., H3K36me2) at ASH1L target genes .

• Target gene identification: Combine ChIP-seq with RNA-seq following ASH1L modulation to identify direct transcriptional targets. For example, in anaplastic thyroid cancer, the pro-oncogenic long noncoding RNA CCAT1 was identified as an ASH1L target .

• In vivo models: Assess tumor growth in xenograft models using ASH1L-depleted cells, followed by immunohistochemistry with ASH1L antibodies to confirm knockdown maintenance .

What are the technical considerations for epitope binning of ASH1L antibodies?

For epitope binning of ASH1L antibodies:

• High-throughput SPR: Use surface plasmon resonance in a classical sandwich assay format to determine whether antibodies compete for the same epitope .

• Array preparation: Immobilize purified antibodies at 1-5 μg/ml in 10 mM sodium acetate (pH 4.5) on an activated surface (e.g., using EDC/SNHS chemistry) .

• Binning analysis: Analyze competition patterns to identify antibodies targeting distinct epitopes of ASH1L. This is particularly important given ASH1L's large size and multiple functional domains .

• Cross-domain binding: Consider the multi-domain architecture of ASH1L (SET domain, AWS domain, BAH domain, bromodomain, PHD-type zinc finger) when interpreting binning results .

• Data visualization: Use industry-standard analysis software that provides intuitive visualization tools to interpret complex binning data .

How can I assess cross-reactivity of ASH1L antibodies with mouse orthologs?

To assess cross-reactivity with mouse orthologs:

• Sequence comparison: Analyze sequence homology between human and mouse ASH1L in the region containing the antibody epitope. Most anti-ASH1L antibodies recognize both human and mouse orthologs due to high sequence conservation .

• Cross-species validation: Test antibody reactivity against both human cell lines (e.g., HeLa, K562, HEK-293T) and mouse cell lines (e.g., G1E, MEFs, murine embryonic stem cells) .

• Allelic cross-reactivity assay: Apply a modified version of the high-throughput SPR approach to evaluate antibody binding to different species variants .

• Immunoblotting: Perform side-by-side Western blots of human and mouse cell lysates to compare detection efficiency and specificity .

• ChIP analysis: Conduct parallel ChIP experiments in human and mouse cells, comparing antibody performance at orthologous genomic loci .

Why might I observe inconsistent results with ASH1L antibodies in ChIP experiments?

Inconsistent results in ASH1L ChIP experiments may occur due to:

• Insufficient cross-linking: ASH1L requires dual cross-linking with both ethylene glycol bis(succinimidyl succinate) and formaldehyde for optimal results .

• Epitope accessibility: Different antibodies (e.g., 296 vs. ab4477) may show slightly different binding patterns due to epitope accessibility issues. For example, ab4477 antibody showed a slight 5' shift in ASH1L occupancy compared to other antibodies .

• Nuclear extraction efficiency: ASH1L is primarily nuclear, and inefficient nuclear extraction may lead to poor results. Ensure proper nuclear extraction protocols are followed .

• Cell type variations: ASH1L binding patterns may vary between cell types. Always validate findings across multiple cell lines when possible .

• Antibody batch variations: Different lots of the same antibody may show varying efficiencies. Include positive controls in each experiment .

How can I differentiate between specific and non-specific signals when using ASH1L antibodies?

To differentiate between specific and non-specific signals:

• Genetic validation: The most definitive approach is to include ASH1L knockdown or knockout samples. Specific signals should be significantly reduced in these samples .

• Multiple antibodies: Use at least two independent antibodies targeting different epitopes of ASH1L. Consistent results across different antibodies suggest specific binding .

• Isotype controls: Include appropriate isotype controls to account for non-specific binding due to the antibody class .

• Known targets: Include primers for known ASH1L targets (positive controls) and non-targets (negative controls) in ChIP-qPCR experiments .

• Signal intensity analysis: ASH1L binds preferentially to active genes. Compare signal intensity between active and inactive genes to assess specificity .

What are the best practices for optimizing ASH1L immunoprecipitation experiments?

For optimal ASH1L immunoprecipitation:

• Nuclear extraction: Use optimized nuclear extraction protocols since ASH1L is predominantly nuclear .

• Antibody amount: Titrate antibody amounts (typically starting with 2-5 μg per IP reaction) to determine optimal concentration for specific pull-down .

• Wash stringency: Balance between stringent washes (to reduce non-specific binding) and preserving specific interactions. Typically, use RIPA buffer with decreasing salt concentrations .

• Elution conditions: For Co-IP experiments, use gentle elution conditions to preserve protein-protein interactions .

• Controls: Include IgG controls and, when possible, ASH1L-depleted samples as negative controls .

How can ASH1L antibodies be used to study the role of ASH1L in DNA damage protection?

To study ASH1L's role in DNA damage protection:

• ChIP-seq before and after UV exposure: Map ASH1L binding patterns before and after UV exposure to identify regions where ASH1L may protect DNA, particularly at enhancers .

• CPD detection: Compare cyclobutane pyrimidine dimer (CPD) formation in ASH1L-bound versus unbound regions after UV exposure .

• ASH1L knockdown studies: Perform ChIP for CPDs in control versus ASH1L-depleted cells to determine if ASH1L depletion increases CPD formation at specific genomic regions .

• Enhancer mutation analysis: Analyze the correlation between ASH1L mutations and enhancer mutations in cancer samples, particularly in melanoma where UV damage is prevalent .

• Mechanistic studies: Investigate if ASH1L's protective role is through direct DNA binding (via its AT hook domains) or through recruitment of repair factors .

What approaches can be used to study the interaction between ASH1L and small molecule inhibitors?

To study ASH1L-inhibitor interactions:

• Binding assays: Use purified ASH1L SET domain for in vitro binding assays with inhibitors, monitoring binding parameters like Kd values .

• Structural studies: Perform crystallography of ASH1L-inhibitor complexes to determine binding sites. For example, AS-99 binds to the autoinhibitory loop region in the SET domain .

• Cellular efficacy: After treatment with inhibitors like AS-99, use ASH1L antibodies in ChIP experiments to assess changes in ASH1L occupancy and H3K36me2 levels at target genes .

• Functional readouts: Analyze changes in cell proliferation, apoptosis, and differentiation in models dependent on ASH1L activity, such as MLL leukemia models .

• Target gene expression: Perform RNA-seq and ChIP-seq to identify genes affected by ASH1L inhibition and correlate with ASH1L binding patterns .

How can I differentiate between catalytic and non-catalytic functions of ASH1L using antibody-based approaches?

To differentiate between catalytic and non-catalytic ASH1L functions:

• Domain-specific antibodies: Use antibodies targeting different domains of ASH1L (SET domain versus other regions) to study domain-specific functions .

• Truncation studies: Generate cells expressing truncated ASH1L proteins lacking specific domains and use antibodies to confirm expression and localization .

• Catalytic inhibitors: Compare phenotypes between ASH1L knockout and treatment with SET domain inhibitors like AS-99, which specifically block catalytic activity .

• Histone modification correlation: Perform dual ChIP for ASH1L and H3K36me2 to identify regions where ASH1L binds but does not catalyze methylation, suggesting non-catalytic functions .

• Protein interaction studies: Use ASH1L antibodies for immunoprecipitation followed by mass spectrometry to identify interaction partners that may mediate non-catalytic functions .